Hydroxyethoxy phenyl butanone, a new cosmetic preservative, does not cause bacterial cross-resistance to antimicrobials by Wesgate, Rebecca et al.
1Hydroxyethoxy phenyl butanone, a new cosmetic preservative, 
does not cause bacterial cross- resistance to antimicrobials
Rebecca Wesgate1, Florence Menard- Szczebara2†, Ahmad Khodr2†, Sylvie Cupferman2 and Jean- Yves Maillard1,*
RESEARCH ARTICLE
Wesgate et al., Journal of Medical Microbiology
DOI 10.1099/jmm.0.001147
Received 31 October 2019; Accepted 24 December 2019; Published 18 March 2020
Author affiliations: 1Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, UK; 2L’Oréal Research and Innovation, 
Chevilly- Larue, France.
*Correspondence: Jean- Yves Maillard,  maillardj@ cardiff. ac. uk
Keywords: resistance; antibiotics; biocides; predictive protocol.
Abbreviations: BSAC, British Society for Antimicrobial Chemotherapy; BZC, benzalkonium chloride; CIP, cirpofloxacin; GEN, gentamicin; HEPB, 
hydroxyethoxy phenyl butanone; I, becoming clinically intermediate; MBC, minimum bactericidal concentration; MIC, minimum inhibitory 
concentration; R and I, Research and Innovation; S, becoming clinically susceptible; TOB, tobramycin; TRI, Triclosan; TSB, tryptone soya broth.
†These authors contributed equally to this work
Ten supplementary figures are available with the online version of this article.
001147 © 2020 The Authors
This is an open- access article distributed under the terms of the Creative Commons Attribution License. This article was made open access via a Publish and Read agreement between 
the Microbiology Society and the corresponding author’s institution.
Abstract
Introduction. Biocide- induced cross- resistance to antimicrobials in bacteria has been described and is a concern for regulators. 
We have recently reported on a new protocol to predict the propensity of biocide to induce phenotypic resistance in bacteria.
Aim. To measure bacterial propensity to develop antimicrobial resistance following exposure to a new cosmetic preservative 
developed by L’Oréal R and I.
Methodology. Well- established antimicrobials including triclosan (TRI) and benzalkonium chloride (BZC) and a new molecule 
hydroxyethoxy phenyl butanone (HEPB) were investigated for their antimicrobial efficacy, effect on bacterial growth, and their 
potential to induce resistance to chemotherapeutic antibiotics using a new predictive protocol.
Results. The use of this predictive protocol with Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa showed 
that TRI and BZC significantly affected bacterial growth, MICs and minimum bactericidal concentrations (MBCs). There was no 
change in antibiotic susceptibility profile following exposure to BZC, but E. coli became intermediate resistant to tobramycin 
following treatment with TRI (0.00002 % w/v). HEPB did not change the antimicrobial susceptibility profile in P. aeruginosa and S. 
aureus but E. coli became susceptible to gentamicin. TRI exposure resulted in bacterial susceptibility profile alteration consist-
ent with the literature and confirmed the use of TRI as a positive control in such a test.
Conclusion. Data produced on the propensity of a molecule to induce bacterial resistance is useful and appropriate when 
launching a new preservative.
InTRoduCTIon
Biocides are antimicrobials that are used for antisepsis, 
preservation and disinfection. They play an important role 
in infection control regimens for eliminating pathogenic 
micro- organisms on hands and inanimate surfaces [1]. 
Their role for preservation is equally important and their 
use is widespread in different industrial environments (e.g. 
food, pharmaceuticals, materials, etc.). Despite the control 
of existing and novel biocide substances commercialized 
in the European market, there has been an increased usage 
of biocides, particularly in consumer- based and healthcare 
products [2, 3]. The overuse and/or sometimes misuse of 
biocides have been seen as a possibility to exacerbate emerging 
antimicrobial resistance in bacteria [2, 3]. The number of 
reports on emerging multidrug- resistant bacteria isolated 
from food and water environments is increasing [4, 5]. 
The possibility of biocide- induced antimicrobial resistance 
is of particular concern [2, 3, 6–8]. The European Biocidal 
Product Regulation (effective from 1 September 2013) request 
manufacturers to provide information on the impact of their 
product and antimicrobial resistance (articles 19- b) ii, 37 and 
47-1/b/. With this in mind, it has become necessary to test 
not only biocide efficacy against targeted micro- organisms 
but also for the risk associated with biocide/biocidal product 
usage on emerging resistance in bacteria [9, 10]. We have 
recently reported the use of protocol based on exposure to 
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‘during use’ concentration of biocides to inform the ability of 
bacteria to develop resistance and cross- resistance to antimi-
crobials. This method is based on evaluating the changes in 
MIC, minimum bactericidal concentration (MBC) and anti-
biotic clinical susceptibility profile of target bacteria before 
and after exposure to a biocide/biocidal product, with the 
stability of phenotypic changes, if any, evaluated. The ‘during 
use’ exposure refers to the product concentration and contact 
time during usage [9]. The use of this protocol enabled us 
to show how targeted bacteria responded to the effect of 
cationic biocides such as benzalkonium chloride (BZC) and 
chlorhexidine preserved products (e.g. shampoo, eye liner) 
[10], and formulated and unformulated hydrogen peroxide 
[10]. In these studies, TRI was used as a ‘positive’ control 
in that it produced significant changes in the susceptibility 
phenotype of targeted Gram- positive and Gram- negative 
bacteria. BZC is a quaternary ammonium compound used 
as a preservative in formulations although it possesses wetting 
and solubilizing properties [11]. TRI is a chlorophenol that 
has been used in a wide variety of applications, spanning from 
preservatives in household products like vacuum cleaners to 
disinfectants, make- up and industrial cleaning agents and 
cosmetics [12–14].
To date, no new antimicrobial molecules have been tested 
with this protocol to investigate possible development of 
bacterial resistance. The present study reports on the use of 
this methodology to test the bacterial response to a novel 
molecule hydroxyethoxy phenyl butanone (HEPB) to be used 
as a preservative agent.
METHodS
Micro-organisms and growth conditions
Pseudomonas aeruginosa ATCC 19429 was cultured from 
working stocks to 10 ml tryptone soya broth (TSB; Oxoid, 
Basingstoke, UK) and incubated for 24 h at 30 °C (±1 °C). 
Staphylococcus aureus NCIMB 9518 and Escherichia coli 
ATCC 8739 were cultured from working stocks to 10 ml TSB 
and incubated for 24 h at 35 °C (±1 °C). Broth cultures were 
centrifuged at 2500 g for 15 min and pellets re- suspended 
in tryptone sodium chloride (TSC; 1 g tryptone l−1 and 8.5 g 
sodium chloride l−1) adjusted to ~108 c.f.u. ml−1.
AnTIMICRobIALS
A preservative molecule obtained from L’Oréal R and I, 
hydroxyethoxy phenyl butanone – 020 001 (HEPB), triclosan 
(TRI; Medex, Warwickshire, UK) and benzalkonium chloride 
(BZC, alkyl distribution C8H17 to C16H33; Fisher Scientific, 
Leicestershire, UK) were investigated. The highest HEPB 
tested concentration of 2 % w/v almost corresponded to 
three times the prospective in use concentration for this new 
preservative in formulae. To solubilize HEPB and TRI, 5 % v/v 
dimethyl sulfoxide (DMSO; Fisher Scientific, Leicestershire, 
UK) was used. The lack of toxicity of the solubilizing agent 
was evaluated using the Bioscreen C analyser (Oy Growth 
Curves AB, Helsinki, Finland). The use of 5 % v/v DMSO 
had no detrimental effect on the growth of the test strains 
(Fig. S1, available in the online version of this article). The 
activity of all preservatives was quenched with a neutral-
izing solution consisting of 1.5 % v/v Tween 80 and 3 % w/v 
lecithin (Fisher scientific, Leicestershire, UK). Neutralizer 
efficacy and toxicity were tested following the experimental 
conditions of Knapp et al. [15]. Briefly, 1 ml of a standard-
ized bacterial inoculum (1×108 c.f.u. ml−1) was added to 9 ml 
of neutralizer for or deionized water (control) for 5 min. 
Survivors were then serially diluted in TSC, and enumerated 
using the standardized Miles and Misra method [16]. The 
neutralizer was considered not toxic since <1 log10 reduction 
was observed following bacterial exposure to the neutralizer. 
The efficacy of the neutralizer to quench the activity of the 
biocides was evaluated by adding 1 ml of bacteria (1×108 
c.f.u. ml−1) to a suspension composed of 1 ml of the highest 
concentration of biocide tested and 8 ml of neutralizer. After 
a 5 min contact time, surviving bacteria were serially diluted 
in TSC and enumerated as described above. As a control, the 
8 ml of neutralizer was replaced with 8 ml of deionized water. 
The neutralizer used was efficacious against all biocides as 
<1 log10 reduction was observed in the neutralized biocide 
suspension.
The following antibiotics were used: ampicillin (10 µg), 
ticarcillin/clavulanic acid (75/10 µg), ciprofloxacin (1 µg), 
tobramycin (10 µg), ceftazidime (30 µg), cefotaxime (30 µg), 
tetracycline (30 µg) and gentamicin (10 µg). All antibiotics 
were purchased from Oxoid.
GRowTH kInETICS
Bacterial growth kinetics with or without preservative was 
determined using the Bioscreen C microbial growth analyser 
based on Gomez Escalada et al. [17]. Each well of the 
Bioscreen plate contained a total volume of 400 µl of bacterial 
suspension (~2×106 c.f.u. well−1) in TSB. The Bioscreen was 
run for 24 h at 25 °C (±1 °C) and readings were taken using a 
wideband filter (420–580 nm) every 15 min preceded by 10 s 
shaking. Controls consisted of TSB, bacteria in TSB±5 % v/v 
DMSO.
Antimicrobial activity and baseline data
A novel predictive protocol was used to evaluate the propen-
sity of micro- organisms to develop resistance to antimi-
crobials [2]. The protocol is based on the evaluation of the 
antimicrobial susceptibility profile before and after exposure 
to an antimicrobial mimicking ‘during use’ conditions of 
the antimicrobial and establishing the stability profile of any 
altered antimicrobial susceptibility profile.
MICs were determined before and after biocide exposure with 
the British Standard EN ISO: 20776–1 (2006) [18] microdilu-
tion protocol. The test inoculum consisted of washed cells (i.e. 
stationary phase) with a bacterial concentration ~106 c.f.u., 
inoculated in TSB in decreasing concentrations of the biocide 
in 96- well plates (ThermoFisher Scientific, Leicestershire, 
UK). The MIC was taken as the lowest concentration of the 
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preservative that showed no growth after 24 h incubation at 
37 °C (±1 °C) or 25 °C (±1 °C).
MBCs were determined by plating out 20 µl of test suspension 
from well of the MIC 96- well plate where no bacterial growth 
was observed and the two lowest biocide concentrations at 
which growth was observed on media (TSA) containing 
10 % v/v neutralizer. After 24 h incubation at 37 °C (±1 °C), 
the MBC was defined as the lowest preservative concentration 
where no bacterial growth occurred.
Antibiotic susceptibility testing
Antibiotic susceptibility testing was performed according to 
the disk diffusion assay described by the British Society for 
Antimicrobial Chemotherapy (BSAC). The clinical interpre-
tation of the zone of inhibition was based on the work of 
Andrews [19].
Exposure to antimicrobial compounds
Micro- organisms were exposed to preservatives in a suspen-
sion test based on the British Standard EN 1276 (2009)
[20]. Briefly, 1 ml of an overnight washed bacterial (1×108 
c.f.u. ml−1) suspension in TSC was added to 9 ml of the of 
a preservative/product (diluted in diH20) for 24 h at 20 °C 
(±1 °C). The concentrations chosen were within the concen-
trations affecting growth or 1/10 of the MIC: for P. aeruginosa: 
0.00063 % w/v BZC, 0.0001 % w/v TRI; for S. aureus 0.00008 % 
w/v BZC, 0.00005 % w/v TRI; and for E. coli 0.00016 % w/v 
BZC, 0.00002 % w/v TRI. For HEPB an arbitrary 0.2 % w/v 
corresponding to 1/10 of the highest concentration tested 
was used for all strains since no MIC could be found for this 
compound. Following exposure, the test micro- organisms 
were filtered through a 0.2 µm filter and washed with 5 ml 
neutralizer followed by 5 ml TSC. The filter was then placed 
in a bottle with 5 ml TSC and 5 g glass beads and vortexed 
for 1 min to recover survivors. Susceptibility testing was 
performed on all survivors after exposure and results were 
compared to baseline data.
Reproducibility
Tests were conducted in triplicate on three separate occasions 
with exception of the microbial growth analyses, that were 
conducted twice. No statistical analysis was conducted on 
antibiotic breakpoints as only the clinical resistance break-
point given by BSAC [19] was of major interest.
RESuLTS
Growth kinetics
The effect of the antimicrobial compounds on the growth 
of the test microorganisms is presented as Supplementary 
Material (Fig. S2–S10). Changes in growth pattern were 
informed by increasing lag phase, change in observed growth 
rate during the exponential phase, and final OD values. The 
control containing 5 % v/v DMSO did not affect the growth 
of test micro- organisms. E. coli and S. aureus started their 
exponential phase faster than P. aeruginosa. Different 
concentrations of BZC inhibited the growth of the test micro- 
organisms: ≥0.013 % w/v for P. aeruginosa, ≥0.0031 % w/v 
for E. coli and ≥0.00078 %w/v for S. aureus (Figs S2, S5, 
S8). Overall, S. aureus growth was severely affected by the 
QAC concentrations tested (Fig. S8). BZC also affected the 
growth of P. aeruginosa at concentrations between 0.0063 and 
0.00039 % w/v, E. coli at concentrations between 0.0016 and 
0.00078 % w/v and S. aureus at a concentration of 0.00039 % 
w/v.
TRI affected but did not inhibit the growth of P. aeruginosa 
(Fig. S3). The effect of TRI was more pronounced against E. coli 
with all concentrations tested affecting bacterial growth (Fig. 
S6). TRI affected the growth of S. aureus in a dose- dependent 
manner, with concentrations >0.005 % w/v being inhibitory, 
and concentrations between 0.025–0.000039 % w/c/ affecting 
the growth rate (Fig. S9). The growth of P. aeruginosa and E. 
coli was inhibited by 2 % w/v HEPB. All other concentrations 
tested affected the final OD in a dose- dependent manner (Fig. 
S4 and S7), although the growth rate of E. coli did not seem 
affected with concentrations <0.5 % w/v, while the growth 
rate of P. aeruginosa was affected with all the concentrations 
tested (Fig. S4). The effect of HEPB on the growth of S. aureus 
was different with concentrations of 2 to 0.5 % w/v affecting 
bacterial growth but not inhibiting it, while concentrations 
<0.25 % w/v had no effect on bacterial growth (Fig. S10).
Change in susceptibility profile following exposure 
to preservatives
Baseline (i.e. pre- exposure) data for the three bacteria against 
the four preservatives were determined using a microdilution 
protocol based on ISO 20776–1 and are shown in Table 1. 
No MIC or MBC were obtained for TRI and P. aeruginosa 
since this bacterium is intrinsically resistant to TRI. P. aerugi-
nosa, S. aureus and E. coli were not susceptible to HEPB at 
the highest concentration of 2 % w/v tested. Changes in the 
susceptibility profile of the bacteria were observed following 
24 h exposure to BZC and TRI. Fold changes in MIC or MBC 
were calculated to help compare MIC or MBC values between 
pre- exposure and post- exposure (Table 1). A 24 h bacterial 
exposure to BZC increased MIC between 1.5- and 8- fold 
overall. For MBC values an increase of 2- to 2.7- fold was 
recorded for P. aeruginosa and E. coli, but the MBC marginally 
decreased for S. aureus by 0.4- fold (Table 1). TRI had a more 
adverse effect on significantly increasing S. aureus and E. coli 
MIC and MBC by >21- and 52- fold, respectively. Changes in 
bacterial susceptibility profile for HEPB at concentrations 
above 2 % w/v could not be tested.
Changes in the bacterial antibiotic susceptibility profiles 
following 24 h exposure to preservatives are shown in Table 2. 
Exposure of E. coli to TRI (0.00002%) altered the antibiotic 
susceptibility profile to tobramycin sufficiently to change the 
clinical interpretation from susceptible to intermediate. S. 
aureus exposure to preservatives for 24 h did not affect its 
antibiotic susceptibility profile. For all three preservatives, 
exposure for 24 h altered the antibiotic susceptibility profile 
of gentamicin sufficiently for change in clinical interpretation 
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from intermediate to susceptible. P. aeruginosa became 
susceptible to ciprofloxacin following exposure to BZC or 
TRI (Table 2).
dISCuSSIon
This study aimed at measuring the effect of 24 h exposure 
to biocide on the change in antimicrobial susceptibility in 
three test bacteria. To date, there is no standard protocol 
to measure the impact of biocide and bacterial resistance 
and cross- resistance. Our protocol allows for exposing 
bacteria to a compound under ‘during use’ conditions [9], 
which reflect the worst- case scenario of product usage such 
as dilution or prolonged exposure during application. Here 
the test compound HEPB is intended to be used as a cosmetic 
preservative agent at a concentration currently permitted 
in EU (0.7 % w/v), hence the long exposure time of 24 h. 
Exposure concentration was chosen as 1/10 of the MIC as a 
worst- case scenario. The major limitation of the study was the 
inability to determine MIC and MBC values for HEPB, which 
were both >2 % w/v for the bacteria tested. This concentration 
was the highest concentration that could be tested at the time 
the experiments were conducted. Although, the alterations 
of MIC/MBC following 24 h exposure to HEPB (0.2 % w/v) 
could not be determined against the bacteria tested, the 
effects of this molecule in altering microbial growth and 
antibiotic susceptibility profile were determined. Exposure 
to HEPB at a 0.2 % w/v concentration for 24 h did not signifi-
cantly affect the antibiotic susceptibility profile of the three 
bacteria. However, it did affect the growth kinetic of P. aerugi-
nosa and E. coli at a concentration ranging 0.016–1 % and 
0.13–1 % w/v, respectively. There were differences in the 
observed ‘inhibitory’ concentrations between the Bioscreen 
Growth Analyser and the ISO 20776–1 protocol, reflecting 
on the impact of using different protocols on measuring anti-
microbial activity. The Bioscreen Growth Analyser is a useful 
automated system that provides additional information on 
the effect (other than inhibitory) of a compound on bacte-
rial growth. It is particularly useful to detect extended lag 
phase and changes in growth kinetics during the log phase 
[17]. HEPB altered the growth kinetics of all bacteria in a 
concentration- dependent manner, indicating a detrimental 
effect on bacterial growth. No MIC was found using the 
standardized ISO method, although a 2 % w/v concentration 
inhibited the growth of both P. aeruginosa and E. coli using 
the Bioscreen Growth Analyser.
Table 1. Mean MIC and MBC for the three test bacteria before and after 24 h exposure to BZC, TRI or HB at 20 °C (±1 °C). Exposure concentrations for 
each biocide/micro- organism combination are given in the text. Fold change was calculated by dividing MIC or MBC values after exposure with the 
values obtained pre- exposure. nd: not determined
Pre- exposure Exposure 24 h Fold change in
  MIC % MBC% MIC% MBC% MIC MBC
BZC
  S. aureus 0.00078 0.0036 0.0063 0.0017 8 0.4
  E. coli 0.0021 0.0031 0.0031 0.0083 1.5 2.7
  P. aeruginosa 0.0063 0.013 0.025 0.025 4 2
Triclosan
  S. aureus 0.00042 0.00021 ≥0.005 ≥0.005 >12 >21
  E. coli 0.00023 0.00025 0.0013 0.0013 5.7 52
  P. aeruginosa ≥0.005 ≥0.005 ≥0.005 ≥0.005 nd nd
Hydroxyethoxy phenyl butanone
  S. aureus ≥2 ≥2 ≥2 ≥2 nd nd
  E. coli ≥2 ≥2 ≥2 ≥2 nd nd
  P. aeruginosa ≥2 ≥2 ≥2 ≥2 nd nd
Table 2. Changes in antibiotic susceptibility profile following 24 h 
exposure to BZC, TRI or HB at 20 °C (±1 °C). Exposure concentrations 
for each biocide/bacteria combination are given in Table 1. Where the 
antibiotic is named, a change to that antibiotic susceptibility profile 
was measured (S: sensitive and I: intermediate) according to BSAC 
breakpoints [19]
Bacteria Change in antibiotic susceptibility profile after 24 h 
exposure to
BZC TRI HEPB
E. coli GEN (S) GEN (S); TOB (I) GEN (S)
P. aeruginosa CIP (S) CIP (S) –
S. aureus – – –
–, no change in susceptibility; AMP, ampicillin; BZC, Benzalkonium 
chloride; CIP, ciprofloxacin; GEN, gentamicin; HEPB, HydroxyEthoxy 
Phenyl Butanone; (I), becoming clinically intermediate; (S), 
becoming clinically susceptible; TIM, ticarcillin/clavulanic acid; 
TOB, tobramycin; TRI, triclosan.
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Different outcomes were observed with the exposure of the 
bacteria to BZC and TRI. Changes in antimicrobial suscepti-
bility profile in Gram- negative bacteria following exposure to 
BZC have been reported with short contact time (5 min) and 
low concentrations (0.0001–0.005 % w/v) of the QAC 10, 15].
The increase in MIC or MBC following exposure to BZC was 
less than 10- fold in all the micro- organisms tested. There was 
no decrease in antibiotic susceptibility in all three bacteria. 
TRI produced more pronounced increase in MIC and MBC in 
the test bacteria, notably in S. aureus with a >12- and >21- fold 
increase, respectively (Table 3). Wesgate et al. [9] observed 
lower increase in MIC and MBC following 24 h exposure to 
TRI at an exposure concentration of 0.0004 % w/v. With E. 
coli, a 32- fold increase in MIC was observed [9] while in this 
study only 6- fold increase was observed although an increase 
in MBC was more significant with a 52- fold. Thus, it appears 
that using the same protocol, the extent in MIC and MBC 
increase depends on the exposure concentration. In addition, 
an increase in MIC/MBC was observed when the exposure 
concentration corresponded to a concentration that affected 
bacterial growth (Table 3). Wesgate et al. [9] already observed 
that MIC/MBC fold changes depended on contact time. The 
concept of a minimum selective concentration (MSC) for 
antibiotics [21] that spans a range of concentrations seems 
also to be the case for biocides. Our findings on the change 
in susceptibility profile to antibiotics when exposed to TRI 
for 24 h are broadly in concordance with those by Wesgate et 
al. [9], except for an increase in tobramycin MIC in E. coli. 
Change in bacterial susceptibility profile when exposed to 
TRI has been well documented [3, 4, 10, 12, 22] and justifies 
the use of the TRI as a positive control for this type of study. 
Muller et al. [23] observed that TRI (20 µM) was associ-
ated with an increased growth rate in P. aeruginosa in the 
presence of tetracycline, piperacillin and chloramphenicol, 
but TRI at 2 or 20 µM did not affect P. aeruginosa growth 
rate without antibiotics. This contrasts with our results with 
lower concentrations of TRI affecting P. aeruginosa growth 
rate. Unfortunately, we did not investigate the mechanisms 
responsible for the observed increase in MIC/MBC to the 
biocides or antibiotics. One reported global mechanism 
that can be associated with increased MIC/MBC to biocides 
and antibiotics in bacteria is the expression of efflux pumps 
(4, 22, 24–28).
Finally, our study investigated the inherent activity of bioc-
ides, but not that of formulated biocides. Formulations can 
negate or decrease the risk of developing bacterial resistance 
following treatment or repeated exposure [9, 10, 29].
Here, a new protocol was designed and used to provide infor-
mation on the ability of a biocide or biocidal product to be 
associated with emerging antimicrobial resistance [2, 9, 10]. 
To this end, the use of TRI as a positive control was particu-
larly appropriate. One limitation of the test for products under 
development is perhaps the difficulty to predict their condi-
tions of use. This protocol relies on the concept of ‘during use’ 
exposure that define both concentration and exposure time 
of the product during use. This enables to set up a worst- case 
scenario for product usage in terms of dilution of the product 
and extended contact time. It is clear from the literature, that 
sub- MIC concentration and long contact time are usually 
more prone to a stable change in antimicrobial phenotype 
[3, 9, 12, 30], although a short contact time of 5 min could 
also be associated with significant MIC/MBC increases and 
changes in antibiotic clinical susceptibility [9, 10]. Measuring 
the effect of biocide during bacterial growth with this protocol 
based on phenotypic changes offers additional information on 
the global effect of biocide on bacteria. Although MIC deter-
mination based on the ISO: 20776–1 (2006) microdilution 
protocol is not directly comparable to the inhibition of growth 
measured with the Bioscreen microbial growth analyser, the 
Table 3. Exposure concentration used and effect of biocides on microbial growth
Microorganisms Biocide Range of concentration 
affecting growth (%w/v)*
24 h exposure concentration 
(%w/v)†
Increase in MIC or MBC‡
MIC MBC
P. aeruginosa BZC 0.0004–0.0063 0.00063 <4 folds <4 folds
TRI 0.01 0.001 – –
HB 0.004–1 0.2 – –
E. coli BZC 0.0016 0.00016 <4 folds <4 folds
TRI 0.00002–0.0025 0.00002 >4 folds >20 folds
HB 1 0.2 – –
S. aureus BZC 0.00004–0.0002 0.00008 >4 folds no increase
TRI 0.0004–0.0025 0.00005 >4 folds >20 folds
HB 0.5–2 0.2 – –
*Range of concentration affecting growth determined with the bioscreen microbial growth analyser
†Exposure concentration defined as 1/10 of MIC determined with the ISO: 20776–1 (2006) microdilution protocol
‡–: not determined
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use of the latter protocol might be useful to define the test 
concentrations that may affect resistance phenotypes.
Using this method, HEPB, a new molecule developed by 
L’Oréal R and I, intended to be used in cosmetic products as 
a new preservative, did not show changes in the antimicrobial 
susceptibility profile in the tested bacteria.
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